Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer,
ranks among the leading causes of cancer-related deaths in the Western world due to …

Pancreatic stellate cells (PSCs) differentiate into cancer-associated fibroblasts (CAFs) that
produce desmoplastic stroma, thereby modulating disease progression and therapeutic …

Single-cell technologies have described heterogeneity across tissues, but the spatial
distribution and forces that drive single-cell phenotypes have not been well defined …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis largely owing to
inefficient diagnosis and tenacious drug resistance. Activation of pancreatic stellate cells …

Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-
acid (ATRA) reprograms pancreatic stroma to suppress pancreatic ductal adenocarcinoma …

Pancreatic ductal adenocarcinomas are distinguished by their robust desmoplasia, or
fibroinflammatory response. Dominated by non-malignant cells, the mutated epithelium must …

Cancer-associated fibroblasts (CAF) constitute a major component of the tumor
microenvironment. Recent observations in genetically engineered mouse models and …

Patient-derived in vivo models of human cancer have become a reality, yet their turnaround
time is inadequate for clinical applications. Therefore, tailored ex vivo models that faithfully …

Cancer‐associated fibroblasts (CAF) are orchestrators of the pancreatic ductal
adenocarcinoma (PDAC) microenvironment. Stromal heterogeneity may explain differential …